Media Summary: American MedChem Nonprofit Corporation is committed to discover and The Pediatric Research Equity Act (PREA) gives the US FDA the authority to require biopharmaceutical companies developing ... International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral

Expediting Drug Development For Children - Detailed Analysis & Overview

American MedChem Nonprofit Corporation is committed to discover and The Pediatric Research Equity Act (PREA) gives the US FDA the authority to require biopharmaceutical companies developing ... International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Day 1, Session 1, Part 1 – Evidence to support pediatric approval through extrapolation BY: Robert “Skip” Nelson, (Johnson ... Closing Remarks and Next Steps: Lynne Yao, FDA About this Event This public workshop was hosted by the FDA/CDER Office of ... Welcome to the Second Global Oncothon in collaboration with SIOP. In this special session, moderated by Shushan Hovsepyan, ...

Welcome and Introduction 1-Welcome and Opening Remarks: Nushin Todd, FDA 2-Introductory Remarks: Theresa Michele, FDA ... Click here to watch the full webinar for free: ... Critical Path Institute's 2023 Scientific Breakthrough Summitwelcomes panelists AJ Alen (I-ACT for Robert Coleman, MBBS, MD, FRCP, FRCPE of Sheffield Cancer Research, University of Sheffield, UK discusses costs of Please join us as our very own Chief Operating Officer, Dr. Cindy Jackson, discusses the complex topic of pediatric

Photo Gallery

Expediting Drug Development for Children with Rare Diseases
How are Medicines Discovered & Developed?
Fostering Pediatric Oncology Drug Development
Current Challenges in Pediatric Drug Development | Robert Ward, MD, FAAP, FCP
New Horizons in Pediatric Drug Development - Day 1, Session 1, Part 1
Nonprescription Analgesic/Antipyretic Drug Development in Children 2 to Less Than 12 Years of Age
How Can We Accelerate New Drug Development for Children with Cancer? | Second Global Oncothon
Nonprescription Analgesic/Antipyretic Drug Development in Children 2 to less than 12 Years of Age
An Overview & Comparison of US and EU Pediatric Drug Development Regulations and Processes
Persistent Issues in Pediatric Drug Development: Challenges and Opportunities
New Horizons in Pediatric Drug Development - Day 1 - Introduction & Welcome
Faster, smarter, less expensive: opinion on drug development costs
Sponsored
Sponsored
View Detailed Profile
Expediting Drug Development for Children with Rare Diseases

Expediting Drug Development for Children with Rare Diseases

American MedChem Nonprofit Corporation is committed to discover and

How are Medicines Discovered & Developed?

How are Medicines Discovered & Developed?

Have you ever wondered how

Sponsored
Fostering Pediatric Oncology Drug Development

Fostering Pediatric Oncology Drug Development

The Pediatric Research Equity Act (PREA) gives the US FDA the authority to require biopharmaceutical companies developing ...

Current Challenges in Pediatric Drug Development | Robert Ward, MD, FAAP, FCP

Current Challenges in Pediatric Drug Development | Robert Ward, MD, FAAP, FCP

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral

New Horizons in Pediatric Drug Development - Day 1, Session 1, Part 1

New Horizons in Pediatric Drug Development - Day 1, Session 1, Part 1

Day 1, Session 1, Part 1 – Evidence to support pediatric approval through extrapolation BY: Robert “Skip” Nelson, (Johnson ...

Sponsored
Nonprescription Analgesic/Antipyretic Drug Development in Children 2 to Less Than 12 Years of Age

Nonprescription Analgesic/Antipyretic Drug Development in Children 2 to Less Than 12 Years of Age

Closing Remarks and Next Steps: Lynne Yao, FDA About this Event This public workshop was hosted by the FDA/CDER Office of ...

How Can We Accelerate New Drug Development for Children with Cancer? | Second Global Oncothon

How Can We Accelerate New Drug Development for Children with Cancer? | Second Global Oncothon

Welcome to the Second Global Oncothon in collaboration with SIOP. In this special session, moderated by Shushan Hovsepyan, ...

Nonprescription Analgesic/Antipyretic Drug Development in Children 2 to less than 12 Years of Age

Nonprescription Analgesic/Antipyretic Drug Development in Children 2 to less than 12 Years of Age

Welcome and Introduction 1-Welcome and Opening Remarks: Nushin Todd, FDA 2-Introductory Remarks: Theresa Michele, FDA ...

An Overview & Comparison of US and EU Pediatric Drug Development Regulations and Processes

An Overview & Comparison of US and EU Pediatric Drug Development Regulations and Processes

Click here to watch the full webinar for free: ...

Persistent Issues in Pediatric Drug Development: Challenges and Opportunities

Persistent Issues in Pediatric Drug Development: Challenges and Opportunities

Critical Path Institute's 2023 Scientific Breakthrough Summitwelcomes panelists AJ Alen (I-ACT for

New Horizons in Pediatric Drug Development - Day 1 - Introduction & Welcome

New Horizons in Pediatric Drug Development - Day 1 - Introduction & Welcome

New Horizons in Pediatric

Faster, smarter, less expensive: opinion on drug development costs

Faster, smarter, less expensive: opinion on drug development costs

Robert Coleman, MBBS, MD, FRCP, FRCPE of Sheffield Cancer Research, University of Sheffield, UK discusses costs of

Why Pediatric Trials Need to Grow up

Why Pediatric Trials Need to Grow up

Please join us as our very own Chief Operating Officer, Dr. Cindy Jackson, discusses the complex topic of pediatric